The generic drug, developed by Roxane Laboratories, is intended to treat excessive daytime sleepiness and cataplexy, which causes a sudden loss of muscle control, in patients with narcolepsy.
Jazz Pharma’s shares fell 6.6 percent to $108 in after-hours trading on Tuesday in response to the approval.
More articles on suppy chain:
Pfizer CEO responds to Trump’s threats against pharma: ‘We need to raise prices’
Short seller predicts Lannett will be first drugmaker to go bankrupt amid price scrutiny
Washington, D.C.-area hospitals desperate for blood donations ahead of inauguration
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.